A former compliance director for the now-shuttered pharmacy compounder Pharmakon Pharmaceuticals Inc. pleaded guilty to distributing subpotent and overpotent compounded drug products to hospitals around the country, illustrating the FDA’s increasing focus on reining in substandard drug compounding practices.
Caprice R. Bearden, of Carmel, Ind., pleaded guilty in the U.S. District Court for the Southern District of Indiana, including to a charge she knowingly conspired to defraud the FDA by obstructing its lawful functions, the Justice Department said Nov. 22. She also pleaded guilty to introducing adulterated drugs into interstate commerce, including opioids nearly 25 times the strength indicated on the labels of the drugs being administered to three infants.
Bearden’s guilty plea comes as the FDA is stepping up its enforcement efforts in the pharmacy compounding area. So far this year, the agency has sent more than 30 warning letters to pharmacy compounders about their noncompliance with current good manufacturing (cGMP) practice requirements. During 2016, the agency sent more than 40 warning letters to compounders.
In drug compounding, a licensed pharmacist combines, mixes, or alters ingredients of a drug to create a medication for an individual patient. Patients in several states received overpotent drugs compounded by Pharmakon, which led to a national recall and the closure of the facility.
The conspiracy charge to which Bearden pleaded guilty carries a maximum sentence of five years in prison and a fine of $250,000 or twice the gross gain or gross loss from the offense, the Justice Department said. The six misdemeanor charges each carry a statutory maximum punishment of one year in prison and a fine of $100,000 or twice the gross gain or gross loss from the offense.
Chief Judge Jane E. Magnus-Stinson accepted the plea but hasn’t yet scheduled a sentencing date.
Read my full story here.
Stay on top of new developments in health law and regulation, and learn more, by signing up for a free trial to Bloomberg Law.
All Bloomberg BNA treatises are available on standing order, which ensures you will always receive the most current edition of the book or supplement of the title you have ordered from Bloomberg BNA’s book division. As soon as a new supplement or edition is published (usually annually) for a title you’ve previously purchased and requested to be placed on standing order, we’ll ship it to you to review for 30 days without any obligation. During this period, you can either (a) honor the invoice and receive a 5% discount (in addition to any other discounts you may qualify for) off the then-current price of the update, plus shipping and handling or (b) return the book(s), in which case, your invoice will be cancelled upon receipt of the book(s). Call us for a prepaid UPS label for your return. It’s as simple and easy as that. Most importantly, standing orders mean you will never have to worry about the timeliness of the information you’re relying on. And, you may discontinue standing orders at any time by contacting us at 1.800.960.1220 or by sending an email to email@example.com.
Put me on standing order at a 5% discount off list price of all future updates, in addition to any other discounts I may quality for. (Returnable within 30 days.)
Notify me when updates are available (No standing order will be created).
This Bloomberg BNA report is available on standing order, which ensures you will all receive the latest edition. This report is updated annually and we will send you the latest edition once it has been published. By signing up for standing order you will never have to worry about the timeliness of the information you need. And, you may discontinue standing orders at any time by contacting us at 1.800.372.1033, option 5, or by sending us an email to firstname.lastname@example.org.
Put me on standing order
Notify me when new releases are available (no standing order will be created)